New Student Offer - HELLO

Join Here

Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose

Published on June 05, 2022
Current Context: The Hyderabad-based company has come up with a booster dose of Corbevax that increased the neutralizing antibody titers in the Covishield and Covaxin groups significantly when compared to placebo.
Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose
  • Recently the Drug Controller General of India (DCGI) approved Biological E’s Corbevax and it becomes the first vaccine to get to be used as a heterologous booster for adults who have either received two shots of Covaxin or Covishield.
  • As of now, India was using a homologous booster shot for all precaution doses. Now, this become the first heterologous booster for adults.
  • Corbevax shot can be booked through the Co-WIN portal by anyone who wished to take a shot.
  • Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
  • Apart from that, it has been claimed that there were no severe or adverse events of interest for 3 months of follow-up after the booster dose was administered.
  • Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73.

Question:

Q.1 DGCA approved Corbevax Booster is a __________type of booster which is used for adults?
a. Homologous
b. Heterologous
c. Mixed
d. Double strain booster
ebook store

About Me

Ramandeep Singh

Ramandeep Singh - Educator

I'm Ramandeep Singh, your guide to banking and insurance exams. With 14 years of experience and over 5000 successful selections, I understand the path to success firsthand, having transitioned from Dena Bank and SBI. I'm passionate about helping you achieve your banking and insurance dreams.

  • Follow me:
Close Menu
Close Menu